2002-2005: As a Post-Doctoral Research Associate, I joined Marcus Peter’s laboratory at the University of Chicago, where we established that engagement of CD95 in malignant cells resistant to the CD95-mediated apoptotic signal triggers non-apoptotic signalling pathways such as NFκB and MAPK (EMBO reports, 2004; EMBO J., 2004). This study drew attention to the potential pro-oncogenic role of CD95.
2005-2009: as a Principal Investigator in the laboratory of Prof. Jean-François Moreau (University of Bordeaux-2, France), we discovered that the redistribution of CD95 into lipid rafts promotes the initial steps of apoptotic signaling (Cell Death and Diff., 2002, Mol. Cell Biol., 2005 and J Immunol., 2006).
Since 2010, as leader of the “Death Receptors & Tumor Escape” (DR@TE) Team (University of Rennes-1, France), we demonstrated that in contrast to membrane-bound CD95L, metalloprotease-cleaved CD95L (cl-CD95L) participates in the progression of i) lupus disease by promoting accumulation of activated T lymphocytes in damaged organs (PLoS Biology, 2011) and ii) triple negative breast cancers by enhancing cell migration of tumor cells (Cancer Res, 2013). In parallel, DR@TE Team dissected the rapid and transient anti-apoptotic role of Ca2+ in the initial steps of CD95 signalling (PNAS, 2011). Overall, these findings revisit the role of CD95 as a death receptor and bring to light its participation in promoting chronic inflammatory disorders.
Since January 2015, we created INSERM OSS lab at the CLCC Eugène Marquis, University of Rennes 1, Rennes.